Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study - Kay, Jonathan; Jaworski, Janusz; Wojciechowski, Rafal; Wiland, Piotr; Dudek, Anna; Krogulec, Marek; Jeka, Slawomir; Zielinska, Agnieszka; Trefler, Jakub; Bartnicka-Maslowska, Katarzyna; Krajewska-Wlodarczyk, Magdalena; Klimiuk, Piotr A.; et al. (Arthritis research & therapy, 2021)
Keywords: Adalimumab; Arthritis; Biological products; Biologics; Biosimilars; Comparative effectiveness; Dictionaries; Drug dosages; FDA approval; Immunogenicity; Immunotherapy; Monoclonal antibodies; Population; Rheumatoid arthritis; Sample size; TNF inhibitors; Tuberculosis; Tumor necrosis factor-TNF; Usability; Poland; Bulgaria; United States--US; Biosimilars; Comparative effectiveness; Immunogenicity; Tumor necrosis factor inhibitors; Biologics; Rheumatoid arthritis; Monoclonal antibodies; Safety; Adalimumab